Wiseguyreports.Com Adds “Onychomycosis -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2023” To Its Research Database
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Onychomycosis in 22 Major Markets
Onychomycosis is a fungal infection of the nail which occurs in the hands or feet. The more notable causative agents include the fungal pathogens Trichophyton rubrum and Trichophyton mentagrophytes. This report provides the current prevalent population for Onychomycosis across 22 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Sweden, Denmark, Finland, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors and prevention, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, patient groups divided by disease classification, aetiology, main symptoms and co-morbidities have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for Onychomycosis include:
• Tinea pedis
• Peripheral vascular disease
• HIV / AIDS
• Osteoarticular disease
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Able to quantify patient populations in global Onychomycosis market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of Onychomycosis and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Useful in the identification and trend of the prevalence numbers for the different causative agents of Onychomycosis.
• Provide a level of understanding on the impact from specific co-morbid conditions on Onychomycosis prevalent population.
• Identify sub-populations within Onychomycosis which require treatment.
• Gain an understanding of the specific markets that have the largest number of Onychomycosis patients.
• LIST OF TABLES AND FIGURES
• CAUSE OF THE DISEASE
• RISK FACTORS & PREVENTION
• DIAGNOSIS OF THE DISEASE
• VARIATION BY GEOGRAPHY/ETHNICITY
• DISEASE PROGNOSIS & CLINICAL COURSE
• KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
• METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
• TOP-LINE PREVALENCE FOR ONYCHOMYCOSIS
• FEATURES OF ONYCHOMYCOSIS PATIENTS
o COMORBIDITIES OF ONYCHOMYCOSIS PATIENTS
• ABBREVIATIONS USED IN THE REPORT
• OTHER BLACK SWAN SERVICES & SOLUTIONS
• REPORTS & PUBLICATIONS
• ONLINE EPIDEMIOLOGY DATABASES
• ONLINE PHARMACEUTICAL PRICING DATABASE
LIST OF TABLES AND FIGURES
• Table 1. Definition of main onychomycosis types
• Table 2. Prevalence of onychomycosis, total (000s)
• Table 3. Prevalence of onychomycosis, males (000s)
• Table 4. Prevalence of onychomycosis, females (000s)
• Table 5. Patients with clinically diagnosed onychomycosis, total (000s)
• Table 6. Clinically diagnosed onychomycosis patients with current active infection, total (000s)
• Table 7. New cases of clinically diagnosed onychomycosis per year, total (000s)
• Table 8. Patients with clinically diagnosed onychomycosis by site of infection, total (000s)
• Table 9. Patients with clinically diagnosed onychomycosis by major clinical presentation type, total (000s)
• Table 10. Patients with clinically diagnosed DLSO by severity, total (000s)
• Table 11. Patients with clinically diagnosed onychomycosis by duration of disease, total (000s)
• Table 12. Patients with clinically diagnosed onychomycosis by causative agent, total (000s)
• Table 13. Patients with clinically diagnosed dermatophyte onychomycosis by type, total (000s)
• Table 14. Patients with clinically diagnosed non-dermatophyte onychomycosis by type, total (000s)
• Table 15. Patients with clinically diagnosed yeast onychomycosis by type, total (000s)
Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (Us) Ph: +44 208 133 9349 (Uk)
Company Name: Wiseguyreports.com
Contact Person: Norah Trent
Email: Send Email
Phone: +1 646 845 9349, +44 208 133 9349